Targeting a 10% reduction in energy and water consumption, and a 30% cut in carbon emissions across facilities by 2025
MKP11093 has shown strong results in preclinical studies with a promising safety and selectivity profile
The payment is in accordance with the agreed contractual terms
Breakthrough UNITY 4D Phaco delivers up to 2X faster nucleus removal and 41% less energy into the eye
New Bay Area building marks significant progress as part of $32 billion US investment projected to create $43 billion in economic value
Argo will receive an upfront payment of $160 million, an option for Profit & Loss split across multiple geographies and potential near-term equity
Kenox to provide formulation and development expertise in orally inhaled and nasal drug products
Lupin will address the observations and respond to the U.S. FDA within the stipulated timeframe
The company has received approval from DCGI to begin patient enrolment and dosing in the country
Subscribe To Our Newsletter & Stay Updated
